View Older Stories View More Recent Stories

Sep 13, 2019 09:00AM Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival
Sep 12, 2019 09:04AM Amgen (AMGN) Announces New Data from KYPROLIS (carfilzomib) & Oncology Pipeline at IMW 2019 Meetings
Sep 12, 2019 09:00AM Amgen Highlights New Data From KYPROLIS® (carfilzomib) And Oncology Pipeline At IMW 2019
Sep 9, 2019 06:29AM Amgen (AMGN) Announces New Data Evaluating Novel Investigational KRAS(G12C) Inhibitor in Larger Patient Group at WCLC
Sep 8, 2019 03:45AM Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Larger Patient Group At WCLC 2019
Sep 5, 2019 04:00PM Amgen To Present At The Morgan Stanley Global Healthcare Conference
Sep 4, 2019 04:00PM Amgen To Webcast Investor Call At IASLC 2019 World Conference on Lung Cancer
Aug 28, 2019 09:00AM New Amgen Data To Be Presented At ESC Congress 2019 Highlight Additional Evidence For Repatha® (Evolocumab) Effectiveness In Cardiovascular Disease Across Multiple Patient Groups
Aug 26, 2019 06:32AM Amgen (AMGN) to Acquire Otezla from Celgene (CELG) for $13.4B
Aug 26, 2019 06:30AM Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion
Aug 26, 2019 06:30AM Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits
Aug 22, 2019 09:00AM Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab)
Aug 9, 2019 04:06PM Amgen (AMGN) Announces it Won Patent Case on Enbrel
Aug 9, 2019 04:05PM Amgen Wins Patent Case On Enbrel® (etanercept)
Aug 2, 2019 04:00PM Amgen Announces 2019 Third Quarter Dividend
Jul 30, 2019 04:01PM Amgen Reports Second Quarter 2019 Financial Results
Jul 25, 2019 04:00PM Amgen Announces Webcast Of 2019 Second Quarter Financial Results
Jul 19, 2019 06:44AM Amgen (AMGN), Allergan (AGN) Report FDA Approval for MVASI (bevacizumab-awwb) and KANJINTI (trastuzumab-anns); Announce U.S. Availability
Jul 18, 2019 11:00PM Amgen And Allergan's MVASI™ (bevacizumab-awwb) And KANJINTI™ (trastuzumab-anns) Now Available In The United States
Jul 11, 2019 04:32PM Amgen (AMGN) Novartis (NVS) & Banner Alzheimer's Institute Report Discontinuation of Clinical Research Program with BACE Inhibitor CNP520
Jul 11, 2019 04:30PM Amgen, Novartis And Banner Alzheimer's Institute Discontinue Clinical Research Program With BACE Inhibitor CNP520 For Alzheimer's Prevention
Jun 28, 2019 06:17AM Amgen (AMGN), UCB Announce Regulatory Update on Status of EVENITY (romosozumab) in EU
Jun 28, 2019 01:00AM Amgen and UCB Provide Regulatory Update on Status of EVENITY™ (romosozumab) in the EU
Jun 25, 2019 04:00PM Amgen And MBC BioLabs Announce Winners Of The Amgen Golden Ticket
Jun 19, 2019 04:02PM Amgen (AMGN) Announces 'Unique' Strategic Research Partnership with The Institute for Protein Design at Univ. of Washington
Jun 19, 2019 04:00PM Amgen And The Institute For Protein Design (IPD) At University Of Washington Announce Unique Strategic Research Partnership
Jun 17, 2019 06:01AM Amgen (AMGN) Highlights BLINCYTO (blinatumomab) Five-Year Overall Survival Data at EHA 2019 Meetings
Jun 16, 2019 02:00AM Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019
Jun 13, 2019 07:13PM FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
Jun 7, 2019 04:00PM Amgen To Present At The Goldman Sachs 40th Annual Global Healthcare Conference
Jun 3, 2019 09:17AM Amgen (AMGN) Announces First Clinical Data Evaluating Novel Investigational KRASG12C Inhibitor AMG 510 at ASCO
Jun 3, 2019 09:00AM Amgen Announces First Clinical Data Evaluating Novel Investigational KRASG12C Inhibitor AMG 510 At ASCO 2019
Jun 2, 2019 10:45AM Amgen Highlights The Versatility Of The BiTE® Immuno-Oncology Platform In Multiple Tumor Types At ASCO 2019
May 29, 2019 04:00PM Amgen To Webcast Investor Meeting At 55th Annual Meeting Of The American Society Of Clinical Oncology (ASCO)
May 28, 2019 04:00PM Amgen Joins With Community Oncology Networks For New Research Collaboration
May 21, 2019 04:00PM Amgen Announces Voting Results Of Annual Meeting Of Stockholders
May 16, 2019 04:00PM Amgen To Present At The RBC Healthcare Conference And The UBS Global Healthcare Conference
May 15, 2019 05:07PM Amgen Showcases Oncology Pipeline At ASCO 2019
May 10, 2019 04:00PM Amgen To Present At The Bank of America Merrill Lynch 2019 Health Care Conference
May 2, 2019 04:34PM Amgen (AMGN) to Highlight Extensive Long-Term Safety And Efficacy Data Of Aimovig at AAN
May 2, 2019 04:30PM Amgen To Highlight Extensive Long-Term Safety And Efficacy Data Of Aimovig® (erenumab-aooe) Across The Spectrum Of Migraine At AAN Annual Meeting
May 2, 2019 04:00PM Amgen (AMGN), Syapse Enter Precision Medicine Collaboration In Oncology
May 2, 2019 04:00PM Amgen And Syapse Enter Precision Medicine Collaboration In Oncology
May 1, 2019 04:00PM Amgen Ignites A Social Fitness Movement To Support The Fight Against Heart Disease And Cancer
Apr 30, 2019 04:01PM Amgen Reports First Quarter 2019 Financial Results
Apr 25, 2019 04:00PM Amgen Announces Webcast of 2019 First Quarter Financial Results
Apr 17, 2019 04:00PM Amgen Foundation Launches Amgen Biotech Experience In Tampa, Florida
Apr 15, 2019 04:04PM Amgen (AMGN) Announces EVENITY Now Available in U.S. For Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
Apr 15, 2019 04:00PM EVENITY™ (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
Apr 9, 2019 03:59PM Amgen (AMGN) Confirms FDA Approves EVENITY For Treatment Of Osteoporosis in Postmenopausal Women
View More Recent Stories View Older Stories